Methotrexate plus ERB-041 for 12 weeks ( DrugBank: Methotrexate )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00141830 (ClinicalTrials.gov) | August 2005 | 30/8/2005 | Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis | A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 3 Oral Doses of ERB-041 in Subjects With Rheumatoid Arthritis on a Background of Methotrexate Therapy | Rheumatoid Arthritis | Drug: Methotrexate plus ERB-041 for 12 weeks;Drug: Placebo for 12 weeks | Wyeth is now a wholly owned subsidiary of Pfizer | NULL | Completed | 18 Years | 80 Years | All | 159 | Phase 2 | United States;Canada;Hungary;Italy;Mexico;Spain |